PET/CT with Pylarify available at ARA


ARA is excited to offer a revolutionary radiotracer for the identification of prostate cancer. PET/CT imaging using the new PSMA targeting radiotracer Pylarify is a big step forward in the initial staging and restaging of metastatic prostate cancer. ARA is currently accepting self-pay patients for Pylarify PET/CT scans, which are FDA approved, but not yet covered by Medicare or private insurance. Medicare coverage is expected to begin in January 2022.

Download flyer to learn more.

Download our updated PET/CT referral form to order PSMA Tracer (Pylarify).

Pylarify is an F-18 labeled prostate-specific membrane antigen (PSMA) radiotracer that is used in PET/CT imaging for men who have been diagnosed with prostate cancer and are suspected to have metastases or who have a history of prostate cancer and are suspected to have a recurrence.


  • Cancer staging and restaging in men with prostate cancer.
  • Greater accuracy in detecting early or very small metastases.
  • Helps providers and patients make informed treatment decisions.
  • Simple preparation instructions.
  • Non-invasive, comfortable PET/CT scans.
For any questions, please contact our Provider Relations team at [email protected] or (512) 799-0806.

Share This Page: